Making Post-Authorization Studies Count: A Smarter Approach to Evidence Planning

Post-authorization studies, including FDA postmarketing requirements (PMRs) and postmarketing commitments (PMCs), represent significant investments for biopharma sponsors. While fulfilling regulatory obligations remains the primary objective, thoughtful planning can help sponsors control costs, reduce operational burden and generate evidence that supports additional regulatory, medical and market access needs.

This white paper explores four practical considerations for making the most of post-authorization research investments. Learn how to tailor study designs to regulatory requirements, anticipate execution challenges, coordinate multiple commitments to reduce duplication and plan for future evidence needs without unnecessary complexity.

Download the white paper to discover how sponsors can meet regulatory expectations more efficiently while maximizing the long-term value of their evidence investments.